Itabe Hiroyuki
Department of Biological Chemistry, Showa University School of Pharmaceutical Sciences, Tokyo, 142-8555, Japan.
Clin Rev Allergy Immunol. 2009 Aug;37(1):4-11. doi: 10.1007/s12016-008-8095-9.
Oxidized low-density lipoprotein (OxLDL) is a well-known risk marker for cardiovascular diseases. OxLDL has shown a variety of proatherogenic properties in experiments performed in vitro. In addition, immunological studies using monoclonal antibodies have revealed the occurrence of OxLDL in vivo in atherosclerotic lesions and patients' plasma specimens. Resent clinical studies have indicated the prospective significance of plasma OxLDL measurements; however, the behavior and metabolism of OxLDL in vivo is poorly understood. The mechanism by which LDL is oxidized is not clear, and the modified structures of OxLDL are not yet fully understood, partly because OxLDL is a mixture of heterogeneously modified particles. Here, I discuss the recent studies on oxidative modifications in OxLDL and its clinical and pathological features.
氧化型低密度脂蛋白（OxLDL）是一种众所周知的心血管疾病风险标志物。在体外实验中，OxLDL已表现出多种促动脉粥样硬化特性。此外，使用单克隆抗体的免疫学研究揭示了OxLDL在动脉粥样硬化病变和患者血浆样本中的体内存在情况。最近的临床研究表明了血浆OxLDL测量的前瞻性意义；然而，OxLDL在体内的行为和代谢仍知之甚少。LDL被氧化的机制尚不清楚，OxLDL的修饰结构也尚未完全了解，部分原因是OxLDL是异质性修饰颗粒的混合物。在此，我将讨论关于OxLDL氧化修饰及其临床和病理特征的最新研究。
